Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b-2, Open-Label Study of JNJ-68284528, A Chimeric Antigen Receptor T-Cell (CAR-T) Therapy Directed Against BCMA in Subjects With Relapsed or Refractory Multiple Myeloma

Trial Profile

A Phase 1b-2, Open-Label Study of JNJ-68284528, A Chimeric Antigen Receptor T-Cell (CAR-T) Therapy Directed Against BCMA in Subjects With Relapsed or Refractory Multiple Myeloma

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 03 Feb 2019

At a glance

  • Drugs LCAR-B38M CAR-T cell therapy (Primary)
  • Indications Multiple myeloma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Janssen Pharmaceuticals
  • Most Recent Events

    • 19 Jul 2018 Status changed from not yet recruiting to recruiting.
    • 05 Jun 2018 New trial record
    • 30 May 2018 According to a Janssen Pharmaceuticals media release, the company scheduled to begin enrollment in the second half of 2018 and follows the U.S. Food and Drug Administration (FDA) clearance of the Investigational New Drug (IND) application submitted by Janssen.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top